Abnova's poised for high-end product market trends for 2024

Abnova Introduces CellTx™ Cell Therapy Reagents, Expands into Cell Therapy Market

Neihu, Taiwan (May 21, 2024)

Abnova is poised on advancing the high-end product markets in NanoAb^TM nanobody catalog reagents, CellTx^TM cell therapy products, and RNAFLEX^TM RNA IVT automation for 2024.

1. NanoAb^TM Nanobody Catalog Reagents

Abnova is the first company in the world producing NanoAb^TM nanobody catalog reagents on a large-scale covering all the duggable targets in the human genome. More importantly, nanobodies have immense applications in CAR T therapy, bispecific and trispecific antibodies, and targeted lipid nanoparticle delivery. These three areas also represent the the manor gaps and unmet needs in the today’s drug development landscape. Abnova’s RUO catalogue nanobodies will not only propel the worldwide research antibody market consumption but also catapult and shorten the drug development cycle for the major diseases in the coming years. Direct translation from RUO nanobodies to clinical drug candidates are feasible, scalable, and more affordable.

2. CellTx^TM Cell Therapy Products

The CellTx^TM products include Human and Mouse CD3/CD28 ActiveBeads™, humanized monoclonal antibodies, and GMP-grade proteins covering the full spectrum of cell therapy applications. Despite the Miltenyi and ThermoFisher CD3/CD28 activation beads market dominance, Abnova aims to capture market share from the these two companies based on already expired patents, stronger technical specification, and improved affordability. Abnova will continue to enhance the product line, ensure the standards and technical requirements, and provide researchers with convenient and reliable tools to drive progress in the cell therapy particular for the treatment of solid tumors.

3. RNAFLEX^TM RNA IVT Automations

The advent of COVID-19 mRNA vaccines has ushered a new era of RNA IVT (in vitro transcription) applications in cancers, autoimmune and chronic diseases. However, the current RNA IVT production relies heavily on labor intensive and stagnant processes compared to the well-established, automations for DNA extraction, amplification, and detection. Manual operations also lead to RNA degradation, batch-to-batch variations, and operational errors, which neagitvely impact experimental results. Built on a strong RNA foundation and experience on all facets of RNA IVT technology and applications, Abnova has launched the world’s first RNAFLEX^TM RNA IVT platform, providing an automated solution to enhance efficiency, reliability, and cost control during RNA manipulation.

As of Q1 this year, Abnova has achieved better earnings per share compared to the same period last year due to diligent cost control and efficient mangement. The three prongs product strategy will drive sales performance for the rest of year.  We also look forward to steady growth performance in the coming years.